<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733213</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-OGR-DUM-2007/1</org_study_id>
    <nct_id>NCT00733213</nct_id>
  </id_info>
  <brief_title>Depiction of Prostate Cancer Treatment Alternatives in Greece</brief_title>
  <official_title>Depiction of Prostate Cancer Treatment Alternatives in Greece</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective, registry analysis of the socio-economic and demographic characteristics of
      patients suffering from locally advanced or metastatic prostate cancer, as well as the
      depiction of the therapeutic algorithms followed in the Greek clinical practice.

        -  Target Group: Patients with locally advanced or metastatic prostate cancer.

        -  The first 10 consecutive patients records that meet the entry criteria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients treated by each treatment alternative.</measure>
    <time_frame>Between 2002 - 2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To depict sociodemographic characteristics and comorbidities.</measure>
    <time_frame>Between 2002 - 2008</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Locally Advanced or Metastatic Prostate Cancer.</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Target Group: Patients diagnosed with Locally advanced or Metastatic Prostate Cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with Locally advanced or Metastatic Prostate Cancer after 2002.

          -  Patients that received Hormonal therapy.

        Exclusion Criteria:

          -  Males that are aged less than 18 years
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Panagiotis Pontikis, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Greece</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karditsa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Serres</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xsanthi</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2008</study_first_submitted>
  <study_first_submitted_qc>August 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2008</study_first_posted>
  <last_update_submitted>October 13, 2009</last_update_submitted>
  <last_update_submitted_qc>October 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr Pontikis Panagiotis, MD Medical and Regulatory Affairs Director</name_title>
    <organization>AstraZeneca, SA Greece</organization>
  </responsible_party>
  <keyword>Prostate Cancer, Treatment alternatives, Metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

